Market Overview

UPDATE: Peregrine Says Preliminary Data From Phase II Study Shows Antiviral Activity and Positive Safety Profile at Both Bavituximab Doses Evaluated

Posted-In: News FDA

 

Related Articles (PPHM)

Around the Web, We're Loving...

Get Benzinga's Newsletters